Journal
JOURNAL OF APPLIED BIOMECHANICS
Volume 28, Issue 2, Pages 184-191Publisher
HUMAN KINETICS PUBL INC
DOI: 10.1123/jab.28.2.184
Keywords
peripheral arterial disease; locomotion; biomechanics; cilostazol; pentoxifylline
Categories
Funding
- Nebraska Research Initiative
- NIH [K25HD047194]
- U.S. Department of Education [H133G080023]
- American Geriatrics Society's Hartford Foundation Dennis W. Jahnigen Award
Ask authors/readers for more resources
Peripheral arterial disease (PAD) is a manifestation of atherosclerosis resulting in intermittent claudication (IC) or leg pain during physical activity. Two drugs (cilostazol and pentoxifylline) are approved for treatment of IC. Our previous work has reported no significant differences in gait biomechanics before and after drug interventions when PAD patients walked without pain. However, it is possible that the drugs are more efficacious during gait with pain. Our aim was to use advanced biomechanical analysis to evaluate the effectiveness of these drugs while walking with pain. Initial and absolute claudication distances, joint kinematics, torques, powers, and gait velocity during the presence of pain were measured from 24 patients before and after 12 weeks of treatment with either cilostazol or pentoxifylline. We found no significant improvements after 12 weeks of treatment with either cilostazol or pentoxifylline on the gait biomechanics of PAD patients during pain. Our findings indicate that the medications cilostazol and pentoxifylline have reduced relevance in the care of gait dysfunction even during pain in patients with PAD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available